ArticleVirchows Archiv : an international journal of pathology2005
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.
Article in Virchows Archiv : an international journal of pathology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 253 citations in OpenAlex.
- Pooled it
- Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.PloS one · 2017Pooled it
- Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.World journal of surgical oncology · 2013Trial
- Somatic genetic alterations in the development and progression in thyroid tumors of follicular cells.European thyroid journal · 2025Review
- Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era.Endocrine-related cancer · 2024Article
- BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population.World journal of surgical oncology · 2024Article
- Unveiling a rare BRAF mutation in minimally invasive follicular thyroid carcinoma: A case report.Medicine · 2024Article
- Review
- Identification of a Novel Non-V600E BRAF Mutation in Papillary Thyroid Cancer.Case reports in endocrinology · 2024Article
- BRAFCancers · 2023Article
- A Comparative Analysis of NOX4 Protein Expression in Malignant and Non-Malignant Thyroid Tumors.Current issues in molecular biology · 2023Article
- Expanding the Spectrum ofInternational journal of molecular sciences · 2023Article
- Preoperative BRAFAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022Article
- Redox Homeostasis in Thyroid Cancer: Implications in NaInternational journal of molecular sciences · 2022Review
- Different Threshold of Malignancy forCancers · 2022Article
- Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling.Frontiers in endocrinology · 2022Article
- TheCancers · 2021Article
- Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma.Cancers · 2021Article
- Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.Endocrine pathology · 2021Review
- Identification of differentially expressed genes and signaling pathways in papillary thyroid cancer: a study based on integrated microarray and bioinformatics analysis.Gland surgery · 2021Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A high prevalence of the BRAF(V600E) somatic mutation was recently reported in several series of papillary thyroid carcinomas (PTC). This mutation appears to be particularly prevalent in PTC with a predominantly papillary architecture. Another BRAF mutation (K601E) was detected in a follicular adenoma and in some cases of the follicular variant of PTC. The few studies on record provided controversial data on the relationship between the occurrence of BRAF mutations and clinicopathologic parameters such as gender, age and tumour staging. In an attempt to clarify such controversies we decided to enlarge our previous series to 315 tumours or tumour-like lesions diagnosed in 280 patients, including a thorough analysis of several clinicopathologic features. The BRAF(V600E) mutation was exclusively detected in PTC with a papillary or mixed follicular/papillary architecture both of the conventional type (46%) and of other histotypes, such as microcarcinoma (43%), Warthin-like PTC (75%) and oncocytic variant of PTC (55%). The BRAF(K601E) mutation was detected in four of the 54 cases of the follicular variant of PTC (7%). The mean age of patients with conventional PTC harbouring BRAF(V600E) (46.7 years) was significantly higher (P<0.0001) than that of patients with conventional PTC without BRAF(V600E) (29.5 years). The BRAF (BRAF(V600E)) mutated PTC did not exhibit signs of higher aggressiveness (size, vascular invasion, extra-thyroid extension and nodal metastasis) and were in fact less often multicentric than PTC without the mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.